Last reviewed · How we verify

NCT03636464: RRTdose

Pharmacokinetics of Antibiotics in Patients Undergoing Renal Replacement Therapies

Recruiting now Last updated 8 February 2023
What this trial tests

trial testing Blood collection in Renal Replacement Therapy in 200 participants. Currently enrolling.

Timeline
1 April 2018
Primary endpoint
1 July 2025
1 July 2026

Quick facts

Lead sponsorCleveland Clinic Abu Dhabi
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment200
Start date1 April 2018
Primary completion1 July 2025
Estimated completion1 July 2026
Sites1 location across United Arab Emirates

Drugs / interventions tested

Conditions studied

Sponsor

Cleveland Clinic Abu Dhabi

Who can join

18 and older, any sex, with Renal Replacement Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is aiming to describe the pharmacokinetic and pharmacodynamic profile of intravenous meropenem, ertapenem, cefepime, colistin, Ceftazidime/Avibactam , Ceftolozane/Tazobactam , and piperacillin/tazobactam in the plasma and determine how much is removed by Renal Replacement Therapies to ensure adequate dosing

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Blood collection

Trials testing the same drug.

Other recruiting trials for Renal Replacement Therapy

Currently open trials in the same condition.

Other Cleveland Clinic Abu Dhabi trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03636464.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing